SPRAVATO® Treatment in [City], [State]

A Different Option for Eligible Adults with Treatment-Resistant Depression

When depression continues despite more than one treatment attempt, it can be difficult to believe that another option will make a difference. You may feel exhausted by medication changes, frustrated by slow progress, or unsure what is left to try.

At [Clinic], we offer SPRAVATO® for eligible adults with treatment-resistant depression. Treatment takes place in a certified healthcare setting under clinical supervision, with monitoring after every dose.

SPRAVATO® is not appropriate for every person. A psychiatric evaluation helps us review your diagnosis, treatment history, current medications, health history, and goals before determining whether it may be an option for you.

What Is SPRAVATO®?

SPRAVATO® is a prescription esketamine nasal spray approved by the U.S. Food and Drug Administration for specific depressive indications in adults.

It may be used:

• Alone or with an oral antidepressant for adults with treatment-resistant depression
• With an oral antidepressant for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior

SPRAVATO® is not a take-home medication. You self-administer it under the direct supervision of a healthcare professional in a certified treatment setting and remain for required monitoring afterward.

Eligibility depends on an individual clinical evaluation.

How Is SPRAVATO® Different from Ketamine?

SPRAVATO® and ketamine are distinct medications with different regulatory statuses and methods of administration.

SPRAVATO® is an FDA-approved esketamine nasal spray for specific depressive indications. It is self-administered in a certified healthcare setting under clinical supervision.

Ketamine is FDA-approved as an anesthetic. Its use for mental health conditions is off-label. At [Clinic], IV Ketamine Infusion Therapy is a separate treatment option with its own clinical considerations.

A psychiatric evaluation helps us determine which care options may be appropriate based on your diagnosis, treatment history, health history, and individual needs.

What to Expect from SPRAVATO® Treatment

SPRAVATO® treatment follows federal safety requirements designed around clinical supervision and monitoring.

Before treatment, a qualified clinician will review your health history, medications, previous treatment experiences, and factors that could affect treatment safety. Your blood pressure will be assessed before administration and monitored afterward because SPRAVATO® can temporarily increase blood pressure.

During your appointment:

• You self-administer SPRAVATO® using a nasal spray device under clinical supervision
• You remain in the healthcare setting after dosing
• Our clinical team monitors you for sedation, dissociation, respiratory effects, blood-pressure changes, and other possible reactions
• You are observed for at least two hours and may remain longer when clinically necessary

Some people experience sedation, dizziness, nausea, changes in perception, or a sense of disconnection from their thoughts, feelings, surroundings, or sense of time. These possible effects are among the reasons treatment must take place in a supervised setting.

You will need to arrange transportation home. Do not drive, operate machinery, or do anything requiring full alertness until the following day after a restful night’s sleep.

Treatment frequency and duration depend on the approved indication, your response, tolerability, and clinical plan. We will explain the recommended schedule if SPRAVATO® is determined to be appropriate for you.

Who May Be a Candidate for SPRAVATO®?

SPRAVATO® may be considered for eligible adults with treatment-resistant depression. This generally means that depression has not improved sufficiently after previous antidepressant treatment attempts.

Determining candidacy involves more than counting how many medications you have tried. We consider your diagnosis, symptoms, previous treatment responses, current medications, and medical and psychiatric history.

Your clinician will also review health conditions, pregnancy considerations, and substance-use history that may affect treatment safety or suitability.

An evaluation does not commit you to treatment or guarantee eligibility. It gives us the information needed to discuss whether SPRAVATO®, IV Ketamine Infusion Therapy, Medication Management, talk therapy, or another care pathway may make sense for you.

Frequently Asked Questions

Can I take SPRAVATO® at home?

No. SPRAVATO® must be self-administered under clinical supervision in a certified healthcare setting. You must remain at the healthcare setting for monitoring after each dose.

How long will I be at the clinic?

Required monitoring continues for at least two hours after dosing. Your complete appointment may take longer depending on preparation, clinical assessment, your response, and when the clinical team determines that you are ready to leave.

Can I drive after treatment?

No. You will need someone to drive you home after every appointment. Do not drive, operate machinery, or do anything requiring full alertness until the following day after a restful night’s sleep.

How quickly does SPRAVATO® work?

Individual responses vary. Clinical studies have evaluated changes in depressive symptoms during short-term and continuing treatment, but no specific result can be promised. We monitor your response over time and determine whether continued treatment remains appropriate.

Does SPRAVATO® prevent suicide?

No. SPRAVATO® has not been shown to prevent suicide or reduce suicidal thoughts or behavior, and it does not replace hospitalization or emergency care when clinically necessary.

If you or someone else may be in immediate danger, call 911 or go to the nearest emergency room. In the United States, you can also call or text 988 to reach the Suicide & Crisis Lifeline.

Will I need to continue taking an oral antidepressant?

For treatment-resistant depression, SPRAVATO® may be prescribed alone or with an oral antidepressant. For depressive symptoms associated with major depressive disorder with acute suicidal ideation or behavior, it is used with an oral antidepressant.

Your clinician will determine what is appropriate for you.

Is SPRAVATO® right for everyone with depression?

No. SPRAVATO® is approved for specific depressive indications and is not appropriate for every person. Eligibility depends on your diagnosis, treatment history, health history, current medications, and individual clinical evaluation.

Start with a Private Conversation

You do not need to decide on a treatment before contacting us. Start with a psychiatric evaluation so we can understand what you have tried, what you are experiencing now, and which options may be appropriate.

Medical Disclaimer

The information on this website is for general educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. The care that may be appropriate for you can only be determined through an individual clinical evaluation.

SPRAVATO® does not replace emergency care or hospitalization when clinically necessary. If you or someone else may be in immediate danger, call 911 or go to the nearest emergency room. In the United States, call or text 988 to reach the Suicide & Crisis Lifeline.

Scientific Resources

1. SPRAVATO® Prescribing Information. U.S. Food and Drug Administration, 2025.
2. SPRAVATO® REMS Program Overview. SPRAVATO® Risk Evaluation and Mitigation Strategy Program, 2025.
3. Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry, 2025.
4. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression. American Journal of Psychiatry, 2019.